ABSTRACT

The present invention found the interaction of CREBL1 and HNF-4α with HtrA2 and revealed for the first time that CREBL1, ATF6, and HNF-4α are degraded by active HtrA2.

In addition, the present invention provides a means for inhibiting the degradation of at least one of CREBL1, ATF6, and HNF-4α, comprising inhibiting the function of HtrA2; a means for preventing and/or treating diabetes, comprising inhibiting the degradation by HtrA2 of at least one of CREBL1, ATF6, and HNF-4α; a means for preventing cell death (for example, pancreatic β cell death), comprising inhibiting the degradation by HtrA2 of CREBL1 and/or ATF6; a means for preventing and/or treating type 2 diabetes, comprising inhibiting the degradation by HtrA2 of HNF-4α; and a reagent kit.